Platinum Investment Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Platinum Investment Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.47M	Sell	137,741 -17,360	-11%	-$444K	1.38%	20
2025 Q4	$3.88M	Sell	155,101 -31,298	-17%	-$793K	0.9%	45
2025 Q3	$4.52M	Sell	186,399 -104,437	-36%	-$1.86M	0.29%	41
2025 Q2	$3.82M	Buy	290,836 +22,949	+9%	+$291K	0.25%	39
2025 Q1	$3.85M	Sell	267,887 -102,391	-28%	-$1.68M	0.22%	34
2024 Q4	$6.2M	Sell	370,278 -59,423	-14%	-$984K	0.36%	30
2024 Q3	$6.87M	Sell	429,701 -66,194	-13%	-$811K	0.31%	31
2024 Q2	$4.48M	Buy	495,895 +10,721	+2%	+$102K	0.18%	41
2024 Q1	$5.48M	Buy	485,174 +104,091	+27%	+$986K	0.22%	39
2023 Q4	$3.03M	Buy	381,083 +43,539	+13%	+$292K	0.12%	68
2023 Q3	$2.18M	Buy	337,544 +165,919	+97%	+$1.14M	0.09%	78
2023 Q2	$1.06M	Buy	+171,625	New	+$814K	0.04%	97

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Platinum Investment Management's CNTA Position: Q1 2026 in Review

Platinum Investment Management reduced its Centessa Pharmaceuticals (CNTA) stake by 11% in Q1 2026, selling an estimated $444K and leaving 137,741 shares worth $5.47M. The position accounts for 1.38% of the portfolio, ranked #20.

Platinum Investment Management first reported a position in CNTA in Q2 2023 and has held it in 12 quarters since. The position peaked at $6.87M in Q3 2024. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Platinum Investment Management held 137,741 shares of Centessa Pharmaceuticals worth $5.47M as of Q1 2026.
Platinum Investment Management sold 17,360 Centessa Pharmaceuticals shares in Q1 2026, an estimated $444K.
Centessa Pharmaceuticals made up 1.38% of Platinum Investment Management's portfolio in Q1 2026, its #20 holding.
Platinum Investment Management first reported a position in Centessa Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Platinum Investment Management's Centessa Pharmaceuticals position peaked at $6.87M in Q3 2024.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Platinum Investment Management's 13F filing for Q1 2026, filed 14 May 2026.